One of the most important tools, and perhaps one of the most confusing tools, for metallurgists is the binary phase diagram.

The Reports and Insights, a leading market research company, has recently releases report titled “Solid Phase Extraction (SPE ...

"FDA grants IND clearance for Innate Pharma’s solid tumour trial" was originally created and published by Clinical Trials ...

Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering clinical-stage oncology company dedicated to transforming the lives of ...

Data demonstrate broad activity of CBX-12 across six tumor types with a strong response rate in TOP1-naïve patients with ovarian (40%; N=10) and ...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the Company will ...

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers. The investigational mRNA cancer immunotherapy is ...

SON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold’ tumors ‘hot’Topline safety data of SB101 Phase 1 study expected ...

with advanced gynecological cancers（Gynecol C）：results from a phase 1 study IBI354（抗HER2 ADC）治疗晚期卵巢癌患者：I期研究结果汇报讲者：舒锦 重庆大学附属肿瘤医院 YL201, a novel B7H3-targeting antibody-drug conjugate（ADC），in ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the U.S Food and Drug Administration (FDA) has cleared its investigational new drug (IND) ...

Regeneron is back with long-term follow-up for its LAG-3 inhibitor and PD-1 inhibitor combo in advanced melanoma, phase 1 ...

Initial results from dose escalation in the first in-human phase 1 trial of DS-9606 suggest early promising clinical activity in patients with advanced solid tumours known to express Claudin-6 (CLDN6) ...